GlassScriptPhysician profile
Ghazaleh Bigdeli
NPI 1003806134
$10,267.70
in general payments reported to CMS, 2019-2025
38 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 81% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $678 · 2021: $663 · 2022: $1,005 · 2023: $3,714 · 2024: $1,646 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,183 · Travel and Lodging: $2,353 · Education: $83.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.54 |
| Travel and Lodging | $2,353.45 |
| Education | $83.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $2,451.03 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $1,713.09 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,058.25 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $452.85 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $446.08 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.14 | 2019-2025 | Ofev |
| Genzyme Corporation | $326.88 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $259.27 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $254.74 | 2019-2025 | Zerbaxa, Dificid |
| Amgen INC. | $246.63 | 2022-2024 | Tezspire |
| Harmony Biosciences LLC | $229.82 | 2020-2025 | Wakix |
| Olympus Corporation of The Americas | $202.01 | 2019 | |
| Pulmonx Corporation | $197.69 | 2024-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $197.63 | 2019-2023 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $194.04 | 2019-2024 | Yupelri |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $169.42 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $160.45 | 2019-2024 | Prolastin-C Liquid |
| Ethicon INC. | $138.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $132.61 | 2021-2022 | |
| Philips North America LLC | $109.70 | 2019-2022 | |
| Intuitive Surgical, INC. | $97.83 | 2023 | Da Vinci Surgical System |
| Novartis Pharmaceuticals Corporation | $89.99 | 2019-2024 | |
| Fisher & Paykel Healthcare INC | $89.76 | 2024-2025 | Fisher & Paykel Healthcare |
| Genentech USA, INC. | $84.36 | 2019-2024 | Xolair |
| Baxter Healthcare | $78.21 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $76.35 | 2023-2024 | Inspire |
| Sunovion Pharmaceuticals INC. | $62.29 | 2019-2020 | |
| Electromed, INC. | $57.61 | 2024 | Smartvest |
| Axsome Therapeutics, INC. | $49.60 | 2022-2025 | Sunosi |
| Sanofi-Aventis U.S. LLC | $45.99 | 2023 | |
| Csl Behring | $44.09 | 2019-2024 | Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $39.69 | 2025 | Glassia |
| Mallinckrodt Enterprises LLC | $31.23 | 2019 | |
| Shionogi INC | $25.86 | 2023 | Fetroja |
| Shire North American Group INC | $24.13 | 2019 | |
| Pfizer INC. | $16.36 | 2024 | |
| Resmed Corp | $11.57 | 2019 | |
| Circassia INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazaleh Bigdeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.